Lymphadenectomy for the management of endometrial cancer

作者：Jonathan Frost, Katie E Webster, Andrew Bryant, Jo Morrison · 发表于：Cochrane Database of Systematic Reviews · 年份：2017 · DOI：10.1002/14651858.cd007585.pub4 · 被引用次数：434 · 研究领域：Endometrial and Cervical Cancer Treatments、Gynecological conditions and treatments、Colorectal Cancer Surgical Treatments

BACKGROUND: This is an update of a previous Cochrane review published in Issue 1, 2010 and updated in Issue 9, 2015. The role of lymphadenectomy in surgical management of endometrial cancer remains controversial. Lymph node metastases can be found in approximately 10% of women who before surgery are thought to have cancer confined to the womb. Removal of all pelvic and para-aortic lymph nodes (lymphadenectomy) at initial surgery has been widely advocated, and pelvic and para-aortic lymphadenectomy remains part of the FIGO (International Federation of Gynaecology and Obstetrics) staging system for endometrial cancer. This recommendation is based on data from studies that suggested improvement in survival following pelvic and para-aortic lymphadenectomy. However, these studies were not randomised controlled trials (RCTs), and treatment of pelvic lymph nodes may not confer a direct therapeutic benefit, other than allocating women to poorer prognosis groups. Furthermore, the Cochrane review and meta-analysis of RCTs of routine adjuvant radiotherapy to treat possible lymph node metastases in women with early-stage endometrial cancer found no survival advantage. Surgical removal of pelvic and para-aortic lymph nodes has serious potential short-term and long-term sequelae. Therefore, it is important to investigate the clinical value of this treatment. OBJECTIVES: To evaluate the effectiveness and safety of lymphadenectomy for the management of endometrial cancer. SEARCH METHODS: We ...